| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.009 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.01 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.01 |